SG11201402876UA - Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof - Google Patents

Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof

Info

Publication number
SG11201402876UA
SG11201402876UA SG11201402876UA SG11201402876UA SG11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA
Authority
SG
Singapore
Prior art keywords
quinolylpyrrolopyrimidyl
fused
salt
ring compound
compound
Prior art date
Application number
SG11201402876UA
Inventor
Takeshi Sagara
Satoru Ito
Sachie Otsuki
Katsumasa Nonoshita
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201402876UA publication Critical patent/SG11201402876UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
SG11201402876UA 2012-02-23 2013-02-22 Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof SG11201402876UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012037565 2012-02-23
PCT/JP2013/054615 WO2013125709A1 (en) 2012-02-23 2013-02-22 Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof

Publications (1)

Publication Number Publication Date
SG11201402876UA true SG11201402876UA (en) 2014-12-30

Family

ID=49005885

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402876UA SG11201402876UA (en) 2012-02-23 2013-02-22 Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof

Country Status (16)

Country Link
US (1) US8889666B2 (en)
EP (1) EP2722332B1 (en)
JP (1) JP5557963B2 (en)
KR (1) KR101660145B1 (en)
CN (1) CN104136438B (en)
CA (1) CA2861980C (en)
DK (1) DK2722332T3 (en)
ES (1) ES2580530T3 (en)
HK (1) HK1202862A1 (en)
HU (1) HUE029343T2 (en)
MX (1) MX351863B (en)
PL (1) PL2722332T3 (en)
RU (1) RU2581039C1 (en)
SG (1) SG11201402876UA (en)
TW (1) TWI496783B (en)
WO (1) WO2013125709A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI558706B (en) * 2013-02-22 2016-11-21 Taiho Pharmaceutical Co Ltd A tricyclic compound and a tricyclic compound which can be produced by the production method
KR101906688B1 (en) * 2013-08-22 2018-10-10 다이호야쿠힌고교 가부시키가이샤 Novel quinoline-substituted compound
CA2980888C (en) * 2015-03-31 2018-03-06 Taiho Pharmaceutical Co., Ltd. Crystal of 3,5-disubstituted benzene alkynyl compound
WO2017064558A1 (en) * 2015-10-14 2017-04-20 大鵬薬品工業株式会社 Novel immunostimulant
JOP20190073A1 (en) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd Selective inhibitor of exon 20 insertion mutant egfr
CN108101905A (en) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 Pyrimido [5,4-b] indolizine or pyrimido [5,4-b] pyrrole biopterin compound, preparation method and the usage
CN111465397B (en) 2017-09-01 2023-10-13 大鹏药品工业株式会社 Selective inhibitors of EGFR mutant at exon 18 and/or exon 21
CN112574208B (en) * 2019-09-29 2022-09-13 深圳市塔吉瑞生物医药有限公司 Substituted fused tricyclic derivatives, compositions and uses thereof
WO2022121967A1 (en) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr tyrosine kinase inhibitor and uses thereof
CN115785107A (en) * 2022-12-15 2023-03-14 南京雷正医药科技有限公司 Substituted 8,9-dihydropyrimido [5,4-b ] indolizine compound, pharmaceutical composition and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601766A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
WO2007075554A2 (en) * 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
KR20150038395A (en) * 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Kinase antagonists
EP2051982A1 (en) * 2006-08-10 2009-04-29 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
SI2526771T1 (en) * 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP2560007A1 (en) * 2007-03-28 2013-02-20 Pharmacyclics, Inc. Identification of bruton's tyrosine kinase inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN102146059A (en) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 Quinazoline derivatives and preparation method and application thereof
US8957065B2 (en) * 2010-06-23 2015-02-17 Hanmi Science Co., Ltd Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
EP2635284B1 (en) * 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
TWI496783B (en) 2015-08-21
WO2013125709A1 (en) 2013-08-29
HK1202862A1 (en) 2015-10-09
MX351863B (en) 2017-10-30
RU2581039C1 (en) 2016-04-10
TW201339160A (en) 2013-10-01
JP5557963B2 (en) 2014-07-23
HUE029343T2 (en) 2017-02-28
US20140057899A1 (en) 2014-02-27
EP2722332A1 (en) 2014-04-23
CA2861980C (en) 2016-11-08
PL2722332T3 (en) 2016-10-31
CA2861980A1 (en) 2013-08-29
KR101660145B1 (en) 2016-09-26
MX2014009991A (en) 2014-09-08
US8889666B2 (en) 2014-11-18
EP2722332B1 (en) 2016-04-20
EP2722332A4 (en) 2014-04-23
KR20140117647A (en) 2014-10-07
AU2013223052A1 (en) 2014-07-03
DK2722332T3 (en) 2016-06-20
JPWO2013125709A1 (en) 2015-07-30
ES2580530T3 (en) 2016-08-24
CN104136438B (en) 2016-04-06
CN104136438A (en) 2014-11-05

Similar Documents

Publication Publication Date Title
IL273276A (en) Salt crystals
EP2842955A4 (en) Trk-INHIBITING COMPOUND
AP2014007810A0 (en) Imidazopyrrolidinone compounds
HK1188451A1 (en) Imidazo-oxazine compound or salt thereof
EP2925129A4 (en) Pro-neurogenic compounds
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (en) Pro-neurogenic compounds
HK1202862A1 (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof
EP2828262A4 (en) Imidazotriazinone compounds
HK1199730A1 (en) Piperidine compound or salt thereof
GB201220843D0 (en) Compound
GB201204125D0 (en) Compounds
SI2836495T1 (en) Tetrahydropyrrolothiazine compounds
HK1185079A1 (en) Novel bicyclic compound or salt thereof
GB201209096D0 (en) Compounds
HK1215571A1 (en) Cobicostat dichlohydrate salt
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
GB201217310D0 (en) Compounds
GB201216448D0 (en) Compound
AU2013223052B2 (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof
GB201222716D0 (en) Compound
GB201218758D0 (en) Compounds